Eli Lilly and Company $LLY Stock: Sumitomo Life Insurance Co. Cuts Holdings

Sumitomo Life Insurance Co. decreased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 1.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,911 shares of the company’s stock after selling 578 shares during the quarter. Eli Lilly and Company comprises approximately 0.7% of Sumitomo Life Insurance Co.’s holdings, making the stock its 18th largest position. Sumitomo Life Insurance Co.’s holdings in Eli Lilly and Company were worth $42,709,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Torren Management LLC raised its holdings in Eli Lilly and Company by 357.1% during the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after buying an additional 25 shares during the period. Foresight Capital Management Advisors Inc. purchased a new position in Eli Lilly and Company in the third quarter valued at about $49,000. Caitlin John LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $64,000. IMG Wealth Management Inc. lifted its stake in Eli Lilly and Company by 500.0% in the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock valued at $72,000 after acquiring an additional 50 shares during the last quarter. Finally, John Boyer Inc. bought a new stake in Eli Lilly and Company in the third quarter worth $72,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

More Eli Lilly and Company News

These are some of the LLY news items that stood out recently:

  • Positive Sentiment: Lilly is expanding its oncology research through the acquisition of Calytrix Bio and a multi-target collaboration with Stipple Bio. The deals add programs and research capabilities, though their financial impact will depend on development progress. Article: Eli Lilly expands its oncology research platform
  • Neutral Sentiment: Recent updates cover studies of brenipatide, LY3839056, tirzepatide, and the cost of Alzheimer’s care. The reports describe study activity or updates, but the supplied information does not identify new efficacy results, so their near-term effect on valuation is unclear. Article: Lilly tests brenipatide in a depression study
  • Negative Sentiment: Some coverage warns that Lilly’s roughly $1.4 trillion valuation leaves substantial expectations embedded in the shares. That could make the stock more sensitive to any slowdown in growth or disappointing clinical results. Article: Eli Lilly’s valuation is heavy with hope

Insider Activity

In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Down 0.3%

Shares of NYSE LLY opened at $1,346.40 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,475.25. The firm has a 50 day moving average price of $1,268.06 and a 200 day moving average price of $1,119.25. The stock has a market cap of $1.27 trillion, a P/E ratio of 43.70, a P/E/G ratio of 1.71 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter last year, the business posted $7.02 EPS. The firm’s revenue was up 38.6% compared to the same quarter last year. Analysts expect that Eli Lilly and Company will post 35.72 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on LLY shares. Wall Street Zen raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. HSBC upped their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research note on Thursday, September 10th. Royal Bank Of Canada reiterated an “outperform” rating and set a $1,600.00 target price on shares of Eli Lilly and Company in a research report on Tuesday. Guggenheim lifted their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research report on Friday, September 18th. Finally, UBS Group increased their price target on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,422.00.

Get Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Further Reading

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.